Amount of eligible people: CDEC reviewed the uncertainty in the amount of patients with moderately severe to critical hemophilia B in Canada eligible for etranacogene dezaparvovec. Medical specialists consulted by CADTH indicated that some clients who are labeled as acquiring mild or average ailment may have a significant bleeding phenotype, which